KRAS/TP53 co-mutations are associated with an inflamed immune microenvironment and increased tumoral programmed death-ligand 1 (PD-L1) expression8–11; However, KRAS/STK11 co-mutated LUADs appear largely “immune-inert”, characterized by a paucity of tumor-infiltrating T cells and lower PD-L1 expression8,10–12. This evidence concerns the gene KRAS and neoplasm.